About 200 reports

  • GLOBAL SCLERODERMA TREATMENT MARKET BY OTHERS DRUG CLASS 2016-2021 ($ MILLIONS)
  • COMPETITIVE SCENARIO

Long-term use of analgesics causes gastrointestinal problems.

  • Dermatological Condition
  • AstraZeneca PLC
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • MERCK & COMPANY
  • PRODUCT DESCRIPTION

SYSTEMIC TETRACYCLINE MAY CAUSE GASTROINTESTINAL UPSET, NAUSEA, DIARRHEA, AND VAGINAL YEAST INFECTION.

  • Dermatological Condition
  • World
  • Market Size
  • Galderma S.A.
  • Valeant Pharmaceuticals International, Inc.
  • Epidemiology Analysis
  • PRICING, REIMBURSEMENT, AND REGULATORY STRATEGY B-244 FOR ACNE AND AD

Patients will be randomized (##:##) to MSB-## or placebo for one week.

  • Dermatological Condition
  • Gastrointestinal Drug
  • Therapy
  • United States
  • Synthetic Biologics
  • DERMATOLOGY PRODUCTS AND R&D PIPELINE - ALLERGAN
  • 10.7 COMPETITIVE ANALYSIS IN ROSACEA MARKET

Particularly PDE-## and PDL-## inhibitors, the market is huge.

  • Dermatological Condition
  • World
  • Forecast
  • Allergan plc
  • Galderma S.A.
  • 2.2 Symptoms
  • 2.1 Therapy Area Overview

Stomach tests involve endoscopies (a popular technique to visualize internal body cavities) and gastrointestinal biopsies (taking a sample from inside the patient' s gastrointestinal tract for analysis).

  • Dermatological Condition
  • World
  • AbbVie Inc.
  • Amryt Pharma plc
  • Celgene Corporation
  • 2.3.3 Psoriasis
  • Appendix

Minor AEs such as stomatitis, headaches, fatigue and gastrointestinal problems such as nausea and vomiting may occur when using Metolate.

  • Dermatological Condition
  • World
  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.

It acquired Salix Pharmaceuticals in 2015 to enter the gastrointestinal segment and divested some of the key brands such as AMBI.

  • Dermatological Condition
  • Forecast
  • Almirall, S.A.
  • Galderma S.A.
  • Valeant Pharmaceuticals International, Inc.

It is growing by ##%-##% year on year.

  • Dermatological Condition
  • Epidemiology
  • World
  • Forecast
  • Market Segment

It is growing by ##%-##% year on year.

  • Dermatological Condition
  • Epidemiology
  • World
  • Forecast
  • Market Segment
  • Vendor landscape

It also focuses on developing and introducing new treatments in the areas of dermatology, neurology, and gastrointestinal disorders.

  • Dermatological Condition
  • World
  • Bayer AG
  • Mylan Inc.
  • Valeant Pharmaceuticals International, Inc.
  • VI. RISK FACTORS
  • a. Approved Products

RISK FACTORS severe acne was related to a higher prevalence of one or more gastrointestinal, sinopulmonary, and psychological co-morbid disorders.

  • Dermatological Condition
  • Allergan plc
  • Foamix Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • a. Approved Products
  • VI. RISK FACTORS

RISK FACTORS severe acne was related to a higher prevalence of one or more gastrointestinal, sinopulmonary, and psychological co-morbid disorders.

  • Dermatological Condition
  • Allergan plc
  • Foamix Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • Dermatology Therapeutics Market, Global, Pipeline Programs Targeting ORAI1, 2017
  • 4.4.3 Psoriasis

It is also in development for various indications in the gastrointestinal, respiratory, and ophthalmology therapy areas.

  • Dermatological Condition
  • World
  • Market Size
  • Allergan plc
  • Apricus Biosciences, Inc.

DERMATOLOGY ONLINE JOURNAL; ##(##): ## EADY EA, ET AL. (1994).

  • Dermatological Condition
  • Foamix Ltd.
  • Galderma S.A.
  • Novan, Inc.
  • Valeant Pharmaceuticals International, Inc.
  • 2.4 Co-morbidities and Complications
  • Pipeline Landscape Assessment

Minor AEs such as stomatitis, headaches, fatigue and gastrointestinal problems such as nausea and vomiting may occur when using methotrexate.

  • Dermatological Condition
  • World
  • Market Size
  • Amgen Inc.
  • Biologics, Inc.
  • FDA
  • Global Acne Grading System

A study reported that severe acne was related to a higher prevalence of one or more gastrointestinal, sinopulmonary, and psychological co-morbid disorders.

  • Dermatological Condition
  • India
  • Allergan plc
  • Cipla Ltd
  • Novartis AG
  • DESCRIPTION OF DISORDERS

Systemic tetracycline may cause gastrointestinal upset, nausea, diarrhea, and vaginal yeast infection.

  • Dermatological Condition
  • Allergan plc
  • Galderma S.A.
  • Pfizer Inc.
  • Valeant Pharmaceuticals International, Inc.

You can easily book an appointment with one online.

  • Acne Treatment
  • Dermatological Condition
  • Pharmaceutical
  • Allergan plc
  • Galderma S.A.

Asian Nursing Research; ##(##): ##-##.

  • Dermatological Condition
  • Actimmune group
  • Anacor Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • GlobalData's company

The company' s digestive health products include diagnostics and therapeutics, gastrointestinal endoscopy products, enteral feeding tubes and accessories.

  • Respiratory Monitoring
  • Eastern Europe
  • Russia
  • Forecast
  • CareFusion Corporation
  • 7 Pipeline Assessment

Asian Nursing Research; ##(##): ##-##.

  • Dermatological Condition
  • Actimmune group
  • Anacor Pharmaceuticals, Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • 7 Pipeline Assessment

Asian Nursing Research; ##(##): ##-##.

  • Dermatological Condition
  • Actimmune group
  • Anacor Pharmaceuticals, Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • 7 Pipeline Assessment

Asian Nursing Research; ##(##): ##-##.

  • Dermatological Condition
  • Actimmune group
  • Anacor Pharmaceuticals, Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.

GASTROINTESTINAL COMPLICATIONS ARE COMMON AND INCLUDE IMPAIRED MOTILITY, DIGESTION, ABSORPTION, AND EXCRETION DUE TO THE ATROPHY OF THE GASTROINTESTINAL (GI) TRACT.

  • Dermatological Condition
  • Epidemiology
  • Forecast
  • GlobalData's company
  • Roche Group

PLOS ONE; ##(##): E##.

  • Dermatological Condition
  • World
  • Allergan plc
  • Cellceutix Corporation
  • Cempra, Inc.
  • 09/15/2017: METRELEPTIN AND LIPODYSTROPHY DATA PRESENTED AT THE INTERNATIONAL MEETING OF PEDIATRIC ENDOCRINOLOGY

The company estimates the prevalence of GL is approximately one in one million people, and the prevalence of the subset of PL being targeted for approval is approximately one half to one in one million people.

  • Dermatological Condition
  • United States
  • Company
  • Demand
  • Novelion Therapeutics Inc.
  • Gastrointestinal
  • Gastrointestinal

Systemic Mastocytosis Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Systemic Mastocytosis Global Clinical Trials Review, H2, 2018" provides an overview of Systemic Mastocytosis clinical trials scenario.This report provides top line data relating to the clinical...

  • Dermatological Condition
  • Therapy
  • World
  • Product Initiative
  • Novartis AG
  • 09/15/2017: METRELEPTIN AND LIPODYSTROPHY DATA PRESENTED AT THE INTERNATIONAL MEETING OF PEDIATRIC ENDOCRINOLOGY

The company estimates the prevalence of GL is approximately one in one million people, and the prevalence of the subset of PL being targeted for approval is approximately one half to one in one million people.

  • Dermatological Condition
  • United States
  • Company
  • Demand
  • Novelion Therapeutics Inc.

PLOS ONE; ##(##): E##.

  • Dermatological Condition
  • Cempra, Inc.
  • Debiopharm Group
  • Melinta Therapeutics, Inc.
  • Merck & Co., Inc.

PLOS ONE; ##(##): E##.

  • Dermatological Condition
  • Cempra, Inc.
  • Debiopharm Group
  • Melinta Therapeutics, Inc.
  • Merck & Co., Inc.